ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1417	National Cancer Institute	Html	en	Stomach (Gastric) Cancer Prevention (PDQ®)–Health Professional Version	Risk factors for stomach (gastric) cancer include certain health conditions (e.g., atrophic gastritis, pernicious anemia, H. pylori infection), genetic factors (e.g., Li-Fraumeni syndrome), or environmental factors (e.g., diet, smoking). Review the evidence on these and other risk factors and interventions to prevent stomach cancer in this expert-reviewed summary.	randomized placebo-controlled trial 0.595383 gastric adenomatous polyps 0.679902 experimental animal models 0.575229 infected family members 0.578256 antioxidant dietary supplements 0.574787 H. pylori 0.663672 annual incidence rates 0.588818 secondary prevention measures 0.572741 age-adjusted incidence rate 0.59463 statistically significant reduction 0.578799 combined antioxidant groups 0.572868 H. pylori infection 0.650947 high H. pylori 0.585004 family members 0.581961 gastric cancer mortality 0.686327 endoscopic resection techniques 0.578064 placebo group 0.585452 chemoprevention trial 0.590009 H. pylori-infected family 0.583244 Li Fraumeni syndrome 0.58425 intestinal metaplasia 0.628781 advanced premalignant lesions 0.570945 protective effects 0.575049 low selenium content 0.586292	statistically significant effect 0.623477 Beta Carotene trial 0.587524 United States 0.702911 gastric cancer incidence. 0.664051 precancerous gastric lesions. 0.647932 5-year survival rate 0.635247 gastric cancer cases 0.674324 gastric cancers 0.625749 gastrointestinal cancers 0.575893 H. pylori-infected people 0.581367 overall 5-year survival 0.57409 beta carotene 0.671292 small randomized trial 0.598139 gastric cancer 0.97116 gastric adenocarcinoma. 0.625249 eradication therapy 0.572355 Chinese medical journal 0.572216 vitamin supplementation 0.570623 statistically significant regression 0.573687 chronic atrophic gastritis 0.586209 gastric cancer. 0.610162 close family members. 0.576811 family history 0.58364 steady incidence rates 0.587586	CLICK HERE
1508	National Cancer Institute	Html	en	AIDS-Related Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of AIDS-Related Lymphoma.	bone marrow involvement. 0.64582 San Francisco Department 0.640611 newly diagnosed AIDS 0.661519 classical HL 0.664649 AIDS-related PCNSL 0.673507 cART era 0.702538 systemic lymphoma 0.656424 Epstein-Barr virus 0.637436 2-year overall survival 0.64874 HIV-infected homosexual men 0.643658 worse median survival 0.6947 median overall survival 0.678448 non-Hodgkin lymphomas 0.64597 patients 0.884787 Burkitt lymphoma 0.731575 certain opportunistic infections 0.656652 AIDS-related lymphomas 0.747647 HIV-associated HL presents 0.728404 immunodeficiency virus type 0.664684 large cell/immunoblastic lymphoma 0.706838 active antiretroviral therapy 0.65426 additional epidemiologic studies 0.641093 AIDS-related lymphoma 0.689324 large B-cell lymphoma 0.712331	human immunodeficiency virus 0.98371 OS rate 0.662052 et al. 0.677948 antiretroviral therapy 0.808834 opportunistic infections 0.717427 AIDS-related CNS infections 0.686364 Hodgkin lymphoma 0.73104 non–HIV-associated HL 0.666192 noncleaved cell lymphoma 0.70352 lymphoma 0.790941 Clin Oncol 0.63995 classical Hodgkin lymphoma 0.712756 lymphocyte-depleted HL 0.665739 anal cancer 0.646441 bone marrow 0.855918 median survival time 0.884464 newly diagnosed HL 0.722202 immunodeficiency virus results 0.662299 primary effusion lymphoma 0.746053 nervous system lymphoma 0.644768 previously diagnosed AIDS 0.751325 immunoblastic non-Hodgkin lymphoma 0.707885 HIV infection 0.640421 cerebral toxoplasmosis 0.679755	CLICK HERE
1543	National Cancer Institute	Html	en	Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult acute lymphoblastic leukemia.	red blood cells 0.657008 treatment 0.69838 cancer treatment 0.510853 stored stem cells 0.432024 myeloid stem cell 0.410543 abnormal cells 0.408626 cord). 0.586593 immature blood cells 0.444877 blast cells 0.409519 CNS prophylaxis 0.43336 cancer cells 0.637541 lymphoid stem cell 0.411207 type 0.407802 chemotherapy 0.418061 PDQ cancer information 0.486683 specific cancer cells 0.45646 clinical trial search 0.434142 white blood cells 0.722058 stem cell 0.530795 treatment clinical trials 0.437953 blood stem cells 0.480973 National Cancer Institute 0.448039 clinical trials 0.958798 mature blood cells 0.496196	Natural killer cells 0.443636 normal cells 0.428739 cancer information summary 0.448111 clinical trial 0.624583 new treatment 0.467045 stem cell transplant 0.495713 kinase inhibitor therapy 0.4731 Lymphoblastic Leukemia Treatment 0.414582 chance leukemia cells 0.460746 patients 0.42006 blood cells 0.731186 bone marrow 0.727339 immature cells 0.419809 CAR T-cell therapy 0.438682 cells 0.839029 cancer clinical trials 0.459465 acute lymphoblastic leukemia 0.946164 radiation therapy 0.527726 Treatment Editorial Board 0.410648 cancer 0.8076 standard treatment 0.454915 tyrosine kinase inhibitor 0.516075 leukemia cells 0.619353	CLICK HERE
1598	National Cancer Institute	Html	en	Nutrition in Cancer Care (PDQ®)–Health Professional Version	Expert-reviewed information summary about the causes and management of nutrition problems that occur in patients with cancer.	Oncology Nutrition Dietetic 0.634094 obese cancer patients 0.674849 World Cancer Research 0.619802 Cancer Research Fund 0.619994 artificial nutrition 0.652387 Community Cancer Centers 0.700876 Cancer Program Guidelines 0.624097 nutrition status 0.695452 nutrition screening 0.627502 Nutrition Therapy section 0.64247 cancer cachexia therapy 0.631345 enteral nutrition 0.709727 patients 0.881369 cancer patients 0.790895 weight loss 0.81132 oral nutrition supplements 0.689897 immunocompromised cancer patients 0.638801 North Central Cancer 0.622864 megestrol acetate 0.683197 Parenter Enteral Nutr 0.674425 nutrition 0.853145 cancer survivors 0.617965 radiation therapy 0.659649 Nutr Clin Pract 0.657573 Nutrition Dietetic Practice 0.630177	et al. 0.712864 treatment 0.690326 lean body mass 0.682169 parenteral nutrition support 0.641552 terminal cancer patients 0.643213 PUBMED Abstract 0.761858 parenteral nutrition 0.727185 Support Care Cancer 0.683396 experimental cancer cachexia 0.632271 oncology nutrition care 0.62028 nutrition care plan. 0.617909 health care 0.624711 Cancer Treatment Group 0.649077 advanced cancer 0.631851 Clin Nutr 0.671517 cancer patients. 0.625985 cancer cachexia 0.838737 Clin Oncol 0.670786 nutrition support therapy 0.618651 systematic review 0.80665 Central Cancer Treatment 0.648181 Cancer J Clin 0.618652 Cancer cachexia syndrome 0.625914 cancer 0.942013	CLICK HERE
1615	National Cancer Institute	Html	en	Cardiopulmonary Syndromes (PDQ®)–Health Professional Version	Expert-reviewed information summary about common conditions that produce chest symptoms. The cardiopulmonary syndromes addressed in this summary are cancer-related dyspnea, malignant pleural effusion, pericardial effusion, and superior vena cava syndrome.	vena cava 0.611223 pericardial tamponade 0.679952 evidence 0.62034 randomized controlled trials 0.605832 malignant pleural effusion 0.70666 pericardial fluid collection 0.700496 significant pericardial effusions 0.706328 underlying malignant disorders 0.602719 right mainstem bronchus 0.652149 chest 0.626465 cancer patients 0.972375 malignant pericardial effusion. 0.719099 Cancer Dyspnea Scale 0.624114 subxiphoid pericardial windows 0.680282 treatment 0.619895 nonmalignant causes 0.594571 Pericardial biopsy 0.658961 pericardial effusions. 0.666377 pericardial sac. 0.661251 dyspneic cancer patients 0.638184 pericardial sclerosis 0.657248 Pericardial friction rubs 0.684646 subxiphoid pericardial window 0.711885 loculated pleural effusions 0.605868 pericardial effusion 0.810932	pericardial sac 0.692904 advanced lung cancer 0.597362 terminally ill patients 0.609314 large pleural effusion 0.611685 pulmonary function tests 0.594337 Pericardial fluid cytology 0.702526 inoperable cancer patients 0.631248 lung cancer patients 0.649316 Recurrent pericardial effusion 0.706493 dyspnea 0.731471 pericardial masses 0.661922 pericardial fluid reaccumulation 0.694759 pericardial mesothelioma 0.66558 respiratory muscle dysfunction 0.634779 inferior vena cava 0.596175 nebulized local anesthetics 0.604885 pericardial sclerotherapy 0.657003 chest pain 0.622877 malignant pericardial effusions 0.808201 pericardial sclerosis. 0.657675 malignant pleural effusions 0.666328 pericardial effusions 0.86832 chest x-ray 0.605659 pericardial drainage 0.663513	CLICK HERE
1620	National Cancer Institute	Html	en	Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of myelodysplastic/myeloproliferative neoplasms including chronic/juvenile myelomonocytic leukemias and atypical CML.	red blood cells 0.768748 cancer treatment 0.388453 blood -forming cells 0.422515 blast cells 0.38801 PDQ cancer information 0.4465 clinical trial search 0.417483 white blood cells 0.789303 myelodysplastic /myeloproliferative neoplasm 0.381874 abnormal blood cells 0.425458 clinical trials 0.736543 mature blood cells 0.494148 myelomonocytic leukemia 0.471388 chronic myelomonocytic leukemia 0.433936 cancer information summary 0.411963 clinical trial 0.54455 patients 0.384599 blood cells 0.912354 chronic myelogenous leukemia 0.426541 immature cells 0.400391 platelets 0.382322 NCI PDQ cancer 0.377587 supportive care 0.382497 Treatment Editorial Board 0.386238 treatment 0.557882	stored stem cells 0.41047 myeloid stem cell 0.393162 immature blood cells 0.507153 blood stem cell 0.390434 cancer cells 0.421289 lymphoid stem cell 0.393903 Easy bruising 0.397179 atypical CML 0.383221 treatment clinical trials 0.403674 blood stem cells 0.764143 National Cancer Institute 0.413265 normal cells 0.378893 juvenile myelomonocytic leukemia 0.471101 new treatment 0.442289 white blood cell 0.40841 healthy red blood 0.434016 bone marrow 0.568618 myelodysplastic/ myeloproliferative neoplasms 0.38491 cells slowly increases 0.413624 cancer clinical trials 0.423855 myelodysplastic/myeloproliferative neoplasm 0.393131 immature white blood 0.444308 treatment options 0.378048 leukemia cells 0.390336	CLICK HERE
1772	National Cancer Institute	Html	es	Complicaciones gastrointestinales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del estreñimiento, la retención fecal, la obstrucción intestinal y la diarrea como complicaciones del cáncer o su tratamiento. Se discute el tratamiento de estos problemas.	Coggrave M 0.462328 Velasco A 0.461355 Ripamonti C 0.458109 Moehl Boatwright ML 0.451889 Curr Pain Headache 0.444995 self-expanding metallic stent 0.516659 diarrea aguda 0.471951 Rectal perforation following 0.463224 radiografía abdominal 0.448054 controlled trial with 0.449945 tracto gastrointestinal distal 0.449681 patients admitted 0.480057 intestinal maligna crónica 0.573598 fármacos causa dependencia 0.472502 malignant bowel 0.527918 Bazzocchi G 0.468893 analgésicos opioides 0.492661 or chemoradiation regimens 0.446129 determinados pacientes 0.452232 Pain Symptom Manage 0.66241 fecal impaction 0.534307 transanal irrigation versus 0.453674 Mosby Year Book 0.447131 Care Cancer 0.448621 fármacos alcaloides 0.46147	Dis Colon Rectum 0.550618 Thomas J 0.454566 Anderson Cancer Center 0.653069 anticolinérgicos opioides 0.50471 spinal cord-injured patients 0.45334 neuropatía autonómica 0.478269 transanal irrigation 0.61955 día expulsa ventosidades 0.465092 Cancer Care 0.446986 Krogh K 0.53282 ¿El paciente usa 0.521414 efecto secundario tardío 0.447263 MD Anderson Cancer 0.654313 retrospective review 0.463703 Clin North Am 0.519081 intestinal progresiva crónica 0.560422 Bruera E 0.519584 Suarez-Almazor M 0.462413 obstrucción mejora 0.544797 palliative care unit 0.529131 obstrucción intestinal aguda 0.896575 aceite mineral 0.990534 Med Clin North 0.445549 imaginología abdominal 0.451038	CLICK HERE
1926	National Cancer Institute	Html	es	Tratamiento de la leucemia de células pilosas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia de células pilosas.	células madre 0.33069 leucemia linfoblástica aguda 0.322509 siguientes afecciones 0.302348 hueso compacto 0.308819 neoplasias mieloides 0.302225 vía oral 0.301703 rayos x 0.301869 gen braf 0.305773 largo plazo 0.304831 célula madre mieloide 0.311776 National Cancer Institute 0.301791 siguientes riesgos 0.301225 células pilosas 0.98731 Instituto Nacional 0.306123 PDQ Tratamiento 0.305303	célula madre linfoide 0.305127 Linfocitos T 0.303214 siguientes problemas 0.302353 leucemia mielógena 0.31078 Drugs Approved 0.301713 Physician Data Query 0.306482 anticuerpo monoclonal rituximab 0.304903 anticuerpo monoclonal usa 0.304464 Hairy Cell Leukemia 0.302945 leucemia mieloide aguda 0.322517 siguientes enlaces 0.301398 célula madre 0.330149 células sanguíneas maduras 0.327581 ósea elabora células 0.315738	CLICK HERE
1989	National Cancer Institute	Html	es	Cuidados médicos de apoyo en niños (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de la peculiaridad de los asuntos que surgen durante y después del tratamiento en los niños con cáncer, y como sobrevivientes adultos de cáncer.	etapa final 0.974283 posibles efectos tardíos 0.445113 células madre 0.448459 adultos jóvenes 0.631616 personas jóvenes 0.478657 posibles tratamientos 0.424654 siguientes aspectos 0.421705 cáncer causa estrés 0.501532 apoyo social escaso 0.437899 siguientes tipos 0.415041 largo plazo 0.418906 efectos tardíos 0.530812 familia reaccionarán 0.418853 National Cancer Institute 0.415958 siguientes riesgos 0.411551	siguientes maneras 0.446878 Instituto Nacional 0.427962 síntomasEl trastorno 0.423462 Cuidado paliativo 0.412419 distintos miembros 0.413316 tratamiento ayuda 0.457106 suicidioUn número 0.419685 siguientes efectos 0.419968 posibles efectos 0.465562 Physician Data Query 0.458553 sistema nervioso central 0.433857 mayores probabilidades 0.421125 Estados Unidos 0.416849 mejores tratamientos 0.417691	CLICK HERE
3517	National Cancer Institute	Html	en	Randomization and Bias in Cancer Clinical Trials	Information about randomization and bias in cancer clinical trials.	different treatments 0.635974 Single-blinded trials 0.587003 treatment 0.879587 instance 0.449169 simplest trial design 0.829657 human choices 0.621077 control group 0.779296 trial 0.855759 example 0.496876 points 0.446685 different health changes 0.763108 randomization 0.811688 bias 0.660255 Double-blinded trials 0.584527 clinical trials 0.60736 end 0.493376 group 0.945379 clinical trial 0.755171	phase 0.504191 new treatment 0.781754 process 0.451025 chance 0.58412 researchers 0.446538 patients 0.774398 trial results 0.587968 treatment trials 0.574174 groups 0.737104 investigational group 0.633981 people 0.445658 way 0.48098 healthier patients 0.602713 treatment group 0.70095 doctors 0.497874 unusual side effects 0.592351 sicker patients 0.596186 standard therapy 0.638086	CLICK HERE